<DOC>
	<DOCNO>NCT02248792</DOCNO>
	<brief_summary>Methotrexate ( MTX ) consider 'gold-standard ' drug treatment severe psoriasis . Health-related quality life ( HRQOL ) impair patient psoriasis , disease severe .</brief_summary>
	<brief_title>Quality Life Patients With Psoriasis Treated With Methotrexate : Prospective , Randomized , Double-blind , Parallel Group Study .</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Age range 18 65 year Both sex Severe plaquetype psoriasis ( BSA &gt; 10 % PASI &gt; 12 ) Pregnancy Lactation Malignancy immunosuppression include HIV Liver disease Renal disease Non compliant Psychiatric illness Hypersensitivity methotrexate past</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>